

“Press release”

Results for the three-month period ended March 31, 2010

Paris, April 22, 2010

Générale de Santé is publishing an operating profit for 1st Quarter 2010 of €76.2m (including €30m resulting from the capital gain on the sale of the medical analysis division in 1st Quarter 2010), an increase of 91%. Revenue was down 3.9%, given the strategy of refocusing the Group's activities, but rose 4.8% in organic growth terms. The Group share of net profit was €46m compared to €12.7m as of March 31, 2009. Before taking into account the impact of the disposal, the Group share of net profit was €17m.

Despite the significant external constraints affecting the Group, particularly with regard to tariffs, with stagnation in Social Security tariffs as of March 1, 2010, Générale de Santé is continuing to invest in training and equipment, as well as in new establishments, both in acute care, subacute care and psychiatry. The Group thus invested €103m in the brand new private hospital L'Estuaire in Le Havre, the result of the combination of two Le Havre clinics, which will open its doors to its first patient on August 1, 2010. In total, five new establishments will open in 2010: three in acute care (Hôpital privé de l'Estuaire in Le Havre, Clinique Jeanne d'Arc in Gien and the extension of Hôpital privé Bon Secours in Arras), the La Roseraie mental healthcare clinic in Soissons and Clinique des Platanes in subacute care in Epinay-sur-Seine.

Générale de Santé thus bolsters its positioning as the premier private actor covering the entire healthcare delivery chain in short to medium term hospital care. The Group's 85 clinics and 25 private hospitals helped care for one million patients in 2009, recruited 3,000 employees and almost 300 doctors.

An exceptional result due to the disposal of the medical analysis division

- **1st Quarter revenue** was down 3.9% based on published figures, mainly as a result of the disposals made in December 2009 and February 2010. Like-for-like, the figures show positive organic growth of 4.8% for the period.
- **Current operating profit:** up 10.4% based on published figures

The improvement in the operating margin (9.3% in 2010 compared to 8.1% in 2009) reflects:

- the favorable impact of slightly higher revenue volumes;
- continuing efforts to control costs with the aim of limiting the impact of a restrictive tariff policy, which is not able to offset rising operating costs;
- the positive effect of professional tax reform.

€m	March 31, 2010	Change	March 31, 2009
Revenue	506.2	- 3.9%	527.0
EBITDA	75.3	+ 6.7%	70.6
Current operating profit	46.9	+ 10.4%	42.5
<i>As % of revenue</i>	9.3%	+ 1.2 point	8.1%
Operating profit*	76.2	+ 91.0%	39.9
Group share of net profit	46.0	+ 262.2%	12.7
Net earnings per share (€)	0.82	+ 256.5%	0.23

* Including about €30m in capital gains arising on the sale of the medical analysis business in February 2010.

Revenue: lower published revenue, but positive organic growth

Consolidated revenue for the three-month period ended March 31, 2010 amounted to €506.2m, down from €572.0m for the same period in 2009.

€m – Not audited	March 2010	March 2009	Change 2010/2009
<i>Ile de France</i>	197.7	186.2	+ 6.2%
<i>Rhône Alpes</i>	80.3	73.9	+ 8.7%
<i>Nord</i>	51.0	50.9	+ 0.2%
<i>Provence Alpes Côte d'Azur</i>	59.6	56.9	+ 4.7%
<i>Burgundy</i>	27.2	26.6	+ 2.3%
<i>Other regions</i>	84.0	79.9	+ 5.1%
<i>Other activities (1)</i>	6.4	52.6	- 87.8%
Published revenue	506.2	527.0	- 3.9%
o/w: - Organic	503.6	480.7	+ 4.8%
o/w organic France	497.7	474.8	+ 4.8%
o/w organic Italy	5.9	5.9	+0.0%
- Changes in scope	2.6	46.3	-

(1) "Other activities" includes non-strategic businesses whose assets have been sold.

Based on published figures, Hospital Care France recorded a 1.8% decline in revenue during the first quarter of 2010. Adjusted to reflect changes in the scope of consolidation, this segment recorded organic growth of 4.8% in the first quarter of 2010, including:

- a +0.4% price effect,
- a +4.4% volume/mix effect.

In France, changes in the scope of consolidation mainly relate to the sale of the Home Care business as of December 31, 2009 and the sale of the Medical Analysis business as of February 2, 2010.

Following the sale of the portion of the Group's Medical Analysis business based in Italy, effective as of December 31, 2009, the entirety of the Group's organic revenue in Italy is now generated by Ospedale Madonna del Popolo in Omegna. This establishment's activity was stable in the first quarter of 2010.

Results – The rise in operating profit, from €39.9m to €76.2m, is chiefly attributable to capital gains of about €30m recorded in the first quarter following the sale of the Medical Analysis business in France.

Stripping out the exceptional capital gain, the operating profit would have been €46.2m, rising 15.8%. This increase reflects intensified efforts relating to the Group's efficiency improvement programs for its establishments: optimizing procurement, updating internal organizations and sharing best practices, controlling overheads and rolling out an IT master-plan. The organic growth achieved confirms the appeal of the Group's establishments and the pertinence of the private hospital model.

The Group share of net profit thus increased from €12.7m as of March 31, 2009 to €46.0m for the same period in 2010, while the total net profit was €17m.

Reduction in the level of net debt – Net financial debt per IFRS was reduced by 9.15% from one year to the next to €836.5m at end-March 2010 compared to €885.8m at end-December 2009 and compared to €920.8m at March 31, 2009. The Net debt / EBITDA ratio also improved to 3.45x.

A constantly improving, high-specification healthcare offering

Many Group projects will be initiated or inaugurated in 2010, thus marking in concrete terms the role that Générale de Santé intends to play in the reorganization of the healthcare landscape specified by the HPST law:

Acute Care:

- Inauguration of Hôpital Privé de l'Estuaire, Le Havre (76)
- Inauguration of Clinique Jeanne d'Arc, Gien (45)
- Inauguration of the maternity unit at Hôpital Privé Bon secours, Arras (62)
- Laying of the foundation stone for Hôpital Privé de Villeneuve d'Ascq (59)
- Laying of the foundation stone for Hôpital Privé Savoie-Nord (74)
- Initiation of work on the extension for Hôpital Privé Paul d'Egine, Champigny-sur-Marne (94)
- Initiation of work on the extension for Hôpital Privé de l'Ouest Parisien, Trappes (78)
- Commissioning of an MRI and scanner at Hôpital Privé de Seine Saint Denis (93)
- Restructuring of the intensive care unit at Hôpital Privé Vert Galand, Tremblay (93) and Clinique Geoffroy Saint Hilaire (75)
- Inauguration of the ophthalmology consultation center at Hôpital Privé La Louvière (59)
- Implementation of the central sterilization unit as part of the Healthcare Cooperation Group in Dijon (Groupement de coopération sanitaire dijonnais, 21)
- Extension of the operating block at Hôpital Privé Saint Martin, Caen (14)
- Inauguration of the chemotherapy department at Hôpital Privé Clairval, Marseille (13)

Subacute care:

- Inauguration of Clinique des Platanes, specialized in addictology, Epinay (93)
- Inauguration of an outpatient department at the clinic CMPR la Provence, Marseille (13)
- Laying of the foundation stone for Clinique de Chatenoy-le-Royal (71)

Mental health:

- Inauguration of a specialized adolescent psychiatry unit in Le Tremblay (93)
- Inauguration of an outpatient department at the Clinique des quatre saisons, Marseille (13)
- Inauguration of Clinique de la Roseraie, Soissons (60)
- Laying of the foundation stone for Clinique Océane, Le Havre (76)
- Laying of the foundation stone for Clinique de Chambray, Montchenain (37)

Full-year outlook for 2010

The Group is continuing, unremittingly to improve its health care offerings to achieve the demanding goals it sets itself, despite a heavily constrained tariff environment.

At constant structure, the Group's aim is therefore to:

- Offset the adverse tariff impact on its EBITDA, notably targeting:
 - ❖ 2–3% organic growth to be achieved notably thanks to the attractiveness of the Group's establishments and an expanded health care offering;
 - ❖ intensified efforts relating to the Group's efficiency improvement programs for its establishments.
- Control the level of net debt, in particular through greater use of external financing, especially for all future projects involving the combination of the activities of existing establishments.

Dates for your diary:

Annual Shareholders' Meeting: May 31, 2010

Publication of interim results: August 2, 2010

Générale de Santé, listed on Compartment A of Euronext Paris (formerly known as the Premier Marché) since June 2001, is included in the Midcac index. Its shares are eligible for the deferred settlement service. As the leading Group in the private hospital care sector in France, Générale de Santé has 21,500 employees, including 7,000 nurses and 4,100 assistant nurses in 110 hospitals and clinics. With 5,500 physicians, it represents the leading independent medical community in France. Générale de Santé provides a complete range of patient care services spanning: acute care, oncology, subacute care and rehabilitation, mental health and homecare. Générale de Santé develops an original healthcare offering, combining medical excellence, organizational efficiency and a human touch; it provides an all-in-one service with an individually-adapted patient support package, before, during and after hospitalization, taking into consideration all of its patients' needs; it takes part in public-service healthcare initiatives and forms part of the nationwide healthcare chain in France.

Code ISIN and Euronext Paris: FR0000044471
Website: www.generale-de-sante.fr

Investor Relations/Analysts:
Emmanuel de Geuser
Tel. + 33 (0)1 53 23 14 89
e.degeuser@gsante.fr

Press Relations:
Gérard Benedetti
Tel. + 33 (0) 1 53 23 14 47
g.benedetti@gsante.fr

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(in million euros)	Period ended 31 march 2009	Period ended 31 march 2010
REVENUES	527.0	506.2
Personnel expenses and profit sharing	(223.7)	(219.5)
Purchased consumables	(107.0)	(96.5)
Other operating income and expenses	(63.5)	(60.3)
Taxes and duties.....	(27.5)	(22.0)
Rents.....	(34.7)	(32.6)
EBITDA	70.6	75.3
Depreciation & amortization.....	(28.1)	(28.4)
Current operating profit	42.5	46.9
Restructuring costs	(1.7)	(1.4)
Profit on management of real estate and financial investments	(0.9)	30.7
Impairment loss on Goodwill.....	--	--
Other non-current income and expense	(2.6)	29.3
Operating profit	39.9	76.2
Cost of gross debt.....	(15.2)	(11.9)
Proceeds from disposal of cash and equivalents.....	0.2	0.1
Net interest expenses	(15.2)	(11.8)
Other financial income	0.2	0.1
Other financial expenses	(1.2)	(1.3)
Other financial income and expenses	(1.0)	(1.2)
Corporate income tax	(9.4)	(15.4)
Associates' net income attributable to the Group.....	--	--
TOTAL NET CONSOLIDATED PROFIT	14.3	47.8
<i>Income and expenses recognized directly in equity</i>		
- Actuarial differences on retirement benefits.....	--	--
- Differences in fair value of financial hedging instruments.....	(9.7)	(2.2)
- Translation difference	(0.1)	--
- Tax effects of income and expenses.....	3.3	0.8
Earnings recognized directly in equity	(6.5)	(1.4)
TOTAL COMPREHENSIVE INCOME	7.8	46.4
BREAKDOWN OF NET PROFIT (in million euros)	Period ended 31 march 2009	Period ended 31 march 2010
- Group's share of net profit	12.7	46.0
- Minority interests.....	1.6	1.8
NET PROFIT	14.3	47.8
BREAKDOWN OF TOTAL COMPREHENSIVE INCOME (in million euros)	Period ended 31 march 2009	Period ended 31 march 2010
- Group's share of total comprehensive income.....	6.2	44.6
- Minority interests.....	1.6	1.8
TOTAL COMPREHENSIVE INCOME	7.8	46.4

CONSOLIDATED BALANCE SHEET - ASSETS

(in million euros)	12-31-2009	At march 31, 2010 (unaudited)
Goodwill	627.9	627.3
Other intangible assets	19.2	20.0
Property, plant and equipment	915.6	914.2
Investments in associates.....	0.1	0.1
Other non-current financial assets.....	28.1	27.8
Deferred tax assets.....	50.5	50.1
NON-CURRENT ASSETS	1,641.4	1,639.5
Inventories	32.8	33.3
Trade and other receivables.....	130.0	159.6
Other current assets	139.9	157.2
Current tax assets.....	2.0	1.3
Current financial assets	13.2	4.5
Cash and cash equivalents.....	---	---
Assets held for sale	56.2	4.8
CURRENT ASSETS	374.1	360.7
TOTAL ASSETS	2,015.5	2,000.2

CONSOLIDATED BALANCE SHEET - LIABILITIES AND EQUITY

(in million euros)	12-31-2009	At march 31, 2010 (unaudited)
Share capital	42.2	42.2
Additional paid-in capital.....	62.5	62.5
Consolidated reserves	320.0	361.6
Group's share of net profit	42.4	46.0
Equity attributable to Group	467.1	512.3
Minority interests.....	10.0	11.9
TOTAL SHAREHOLDERS' EQUITY	477.1	524.2
Borrowings	702.4	734.6
Provisions for retirement and other employee benefits.....	29.7	30.5
Non-current provisions.....	37.3	34.9
Other non-current liabilities.....	35.4	37.3
Deferred tax liabilities	81.3	80.7
NON-CURRENT LIABILITIES	886.1	918.0
Current provisions.....	13.8	14.3
Accounts payable.....	124.1	139.2
Other current liabilities	296.2	291.0
Tax liabilities due	0.6	14.4
Short-term borrowings	154.7	62.1
Bank overdraft.....	5.1	32.2
Liabilities related to assets held for sale.....	57.8	4.8
CURRENT LIABILITIES	652.3	558.0
TOTAL LIABILITIES AND EQUITY	2,015.5	2,000.2

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(in million euros)	SHARE CAPITAL	ADDITIONAL PAID IN CAPITAL	RESERVES	EARNINGS DIRECTLY RECOGNIZED IN EQUITY	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	GROUP'S SHARE OF EQUITY	MINORITY INTERESTS	SHAREHOLDERS' EQUITY
Shareholders' equity at December 31, 2009	42.2	62.5	340.2	(20.2)	42.4	467.1	10.0	477.1
Share issue (including net fees)	--	--	--	--	--	--	--	--
Treasury shares	--	--	--	--	--	--	--	--
Stock options and restricted stocks	--	--	0.6	--	--	0.6	--	0.6
Prior year appropriation of earnings	--	--	42.4	--	(42.4)	--	--	--
Distribution of dividends	--	--	--	--	--	--	--	--
Change in consolidation scope	--	--	--	--	--	--	0.1	0.1
Total comprehensive income for the year	--	--	--	(1.4)	46.0	44.6	1.8	46.4
Shareholders' equity at March 31, 2010 (unaudited)	42.2	62.5	383.2	(21.6)	46.0	512.3	11.9	524.2

STATEMENT OF INCOME AND EXPENSES RECOGNIZED DIRECTLY IN SHAREHOLDERS' EQUITY

(in million euros)	12-31-2008	Income and expenses 2008	12-31-2009	Income and expenses at March 31, 2010	At march 31, 2010 (unaudited)
Translation difference.....	(0.3)	--	(0.3)	--	(0.3)
Actuarial difference on retirement commitments	(5.1)	1.1	(4.0)	--	(4.0)
Fair value of financial hedging instruments	(14.2)	(1.7)	(15.9)	(1.4)	(17.3)
Income and expenses recognized directly in equity	(19.6)	(0.6)	(20.2)	(1.4)	(21.6)

CONSOLIDATED CASH FLOW AND FINANCING STATEMENT (unaudited)

(in million euros)	Period ended 31 march 2009	Period ended 31 march 2010
Total net consolidated profit.....	14.3	47.8
Depreciation & amortization.....	28.1	28.4
Other non-current income and expenses.....	2.6	(29.3)
Share of net profit of associates.....	--	--
Other financial income and expenses.....	1.0	1.2
Net interest expenses.....	15.2	11.8
Corporate income tax.....	9.4	15.4
EBITDA	70.6	75.3
Non-cash items including provisions and reversals (transactions with no cash effect).....	(3.7)	0.3
Other paid non-current income and expenses.....	(1.4)	(1.6)
Changes in other non-current assets and liabilities.....	(0.4)	0.1
Cash flow before net interest expenses & taxes	65.1	74.1
Corporate income tax paid.....	(2.8)	(0.2)
Change in working capital requirements.....	(35.2)	(29.3)
NET CASH FROM OPERATING ACTIVITIES: (A)	27.1	44.6
Purchase of property, plant & equipment and intangible assets.....	(31.1)	(28.0)
Proceeds from sale of tangible and intangible assets.....	0.5	--
Purchase of entities.....	(10.7)	(0.7)
Proceeds from the disposal of entities.....	7.5	53.3
Dividends from non consolidated companies.....	--	--
NET CASH USED FOR INVESTING ACTIVITIES: (B)	(33.8)	24.6
Share issue: (a).....	--	--
Share issues by subsidiaries subscribed to by third parties (b).....	--	--
Extraordinary distribution of additional paid-in capital: (c).....	--	--
Dividends paid to GDS shareholders: (d).....	--	--
Dividends paid to minority interests of consolidated companies: (e).....	(0.5)	--
Net interest expense paid: (f).....	(15.2)	(11.8)
Loan issuance charges: (g).....	--	--
Cash flow before repayment of borrowings: (h) = (A+B+a+b+c+d+e+f+g).....	(22.4)	57.4
Increase in borrowings: (i).....	40.0	20.0
Repayment of borrowings: (j).....	(6.1)	(117.5)
NET CASH USED FOR FINANCING ACTIVITIES: (C) = a + b + c + d + e + f + g + i + j	18.2	(109.3)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS: (A + B + C)	11.5	(40.1)
Reclassification of cash in assets held for sale.....	---	13.0
Opening cash position.....	(6.8)	(5.1)
Closing cash position.....	4.7	(32.2)
Net debt at beginning of period	913.0	885.8
Cash flow before repayment of borrowings: (h).....	22.4	(57.4)
Capitalization of financial leases.....	0.4	1.8
Capitalization of loan issuance costs.....	0.9	0.9
Assets held for sale.....	(0.9)	--
Fair value of financial hedging instruments.....	6.4	1.4
Change in consolidation scope and other.....	(21.4)	4.0
Net debt at end of period	920.8	836.5